[Show abstract][Hide abstract] ABSTRACT:
Abstract AL amyloidosis results from extracellular deposition of fibril-forming monoclonal immunoglobulin light chains (LC) usually secreted by a plasma cell (PC) clone. Misfolded LCs deposit as unique fibrils leading to organ failure and eventually death. Survival for untreated patients remains poor and restrictive cardiomyopathy, nephrotic syndrome or hepatic failure greatly worsen outcome. Conventional chemotherapy and novel therapy with immunomodulatory drugs or proteasome inhibitors (PI) eradicates PC but generates adverse toxicities and sustained responses are limited. Moreover, only 20% of AL amyloidosis patients are eligible for stem cell transplantation. The molecular events deregulated in AL amyloidosis remain undefined and effective therapies based upon the biology of disease are lacking. Impressive hematologic response rates obtained with bortezomib provide practice-changing data to advocate their introduction early in the treatment course. Bortezomib and the emerging second-generation PI alone or combined with dexamethasone and alkylating agents may enhance hematologic and organ responses in AL amyloidosis.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.